Search hospitals > California > Davis

Sutter Davis Hospital

Claim this profile
Davis, California 95616
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
96 reported clinical trials
7 medical researchers
Photo of Sutter Davis Hospital in DavisPhoto of Sutter Davis Hospital in DavisPhoto of Sutter Davis Hospital in Davis

Summary

Sutter Davis Hospital is a medical facility located in Davis, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Davis Hospital is involved with conducting 96 clinical trials across 257 conditions. There are 7 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Edmund W. Tai.

Area of expertise

1Cancer
Global Leader
Sutter Davis Hospital has run 46 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Sutter Davis Hospital has run 21 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
HER2 positive

Top PIs

Clinical Trials running at Sutter Davis Hospital

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer
Renal Cell Carcinoma
Meningioma
Pancreatic Cancer
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Chemotherapy Reduction After Surgery

for Breast Cancer

This study is evaluating whether a combination of drugs may help treat breast cancer.
Recruiting1 award Phase 227 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Sutter Davis Hospital?
Sutter Davis Hospital is a medical facility located in Davis, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Sutter Davis Hospital is involved with conducting 96 clinical trials across 257 conditions. There are 7 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Edmund W. Tai.